Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a significant milestone in the development of PC111, a first-in-class anti-Fas Ligand monoclonal antibody, following Dr. Roberta Lotti of Pincell Srl receiving the 'Oscar of Italian Dermatology' from SIDeMaST. The award recognizes Dr. Lotti's research on PC111, which has demonstrated the ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris, a severe autoimmune skin condition. Published under the title 'Blocking soluble Fas Ligand ameliorates pemphigus', the study highlights PC111's potential as a non-immunosuppressive, disease-modifying treatment.

Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its significance in addressing large unmet medical needs in the field of inflammation and immunology. This breakthrough not only marks a pivotal moment in dermatological research but also positions Scinai at the forefront of developing innovative treatments for autoimmune diseases. For more details on the announcement, visit https://ibn.fm/51v14.